Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 1002 results for public health medicine & health

  1. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

  2. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

  3. Secukinumab for treating relapsed polymyalgia rheumatica ID6599: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 22 July 2026.

  4. Secukinumab for treating relapsed polymyalgia rheumatica ID6599

    In development Reference number: GID-TA11806 Expected publication date: TBC

  5. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628

    In development Reference number: GID-TA11826 Expected publication date: TBC

  6. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    Awaiting development Reference number: GID-TA11813 Expected publication date: TBC

  7. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 13 August 2026.

  8. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625

    In development Reference number: GID-TA11815 Expected publication date: TBC

  9. Sole supplied titles

    Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.

  10. Get involved

    Tell us what matters to you, your organisation or your community.

  11. Get involved

    Tell us what matters to you, your organisation or your community.

  12. Percutaneous thrombectomy for intermediate-risk and high-risk acute pulmonary embolism

    In development Reference number: GID-HTG10169 Expected publication date:  07 April 2027

  13. NICE-wide topic prioritisation: the manual (PMG46)

    This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board

  14. Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date:  13 January 2027

  15. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC